RATIONALE: Ineffective repair of a damaged alveolar epithelium has been postulated to cause pulmonary fibrosis. In support of this theory, epithelial cell abnormalities, including hyperplasia, apoptosis, and persistent denudation of the alveolar basement membrane, are found in the lungs of humans with idiopathic pulmonary fibrosis and in animal models of fibrotic lung disease. Furthermore, mutations in genes that affect regenerative capacity or that cause injury/apoptosis of type II alveolar epithelial cells have been identified in familial forms of pulmonary fibrosis. Although these findings are compelling, there are no studies that demonstrate a direct role for the alveolar epithelium or, more specifically, type II cells in the scarring process. OBJECTIVES: To determine if a targeted injury to type II cells would result in pulmonary fibrosis. METHODS: A transgenic mouse was generated to express the human diphtheria toxin receptor on type II alveolar epithelial cells. Diphtheria toxin was administered to these animals to specifically target the type II epithelium for injury. Lung fibrosis was assessed by histology and hydroxyproline measurement. MEASUREMENTS AND MAIN RESULTS: Transgenic mice treated with diphtheria toxin developed an approximately twofold increase in their lung hydroxyproline content on Days 21 and 28 after diphtheria toxin treatment. The fibrosis developed in conjunction with type II cell injury. Histological evaluation revealed diffuse collagen deposition with patchy areas of more confluent scarring and associated alveolar contraction. CONCLUSIONS: The development of lung fibrosis in the setting of type II cell injury in our model provides evidence for a causal link between the epithelial defects seen in idiopathic pulmonary fibrosis and the corresponding areas of scarring.
RATIONALE: Ineffective repair of a damaged alveolar epithelium has been postulated to cause pulmonary fibrosis. In support of this theory, epithelial cell abnormalities, including hyperplasia, apoptosis, and persistent denudation of the alveolar basement membrane, are found in the lungs of humans with idiopathic pulmonary fibrosis and in animal models of fibrotic lung disease. Furthermore, mutations in genes that affect regenerative capacity or that cause injury/apoptosis of type II alveolar epithelial cells have been identified in familial forms of pulmonary fibrosis. Although these findings are compelling, there are no studies that demonstrate a direct role for the alveolar epithelium or, more specifically, type II cells in the scarring process. OBJECTIVES: To determine if a targeted injury to type II cells would result in pulmonary fibrosis. METHODS: A transgenicmouse was generated to express the human diphtheria toxin receptor on type II alveolar epithelial cells. Diphtheria toxin was administered to these animals to specifically target the type II epithelium for injury. Lung fibrosis was assessed by histology and hydroxyproline measurement. MEASUREMENTS AND MAIN RESULTS:Transgenic mice treated with diphtheria toxin developed an approximately twofold increase in their lung hydroxyproline content on Days 21 and 28 after diphtheria toxin treatment. The fibrosis developed in conjunction with type II cell injury. Histological evaluation revealed diffuse collagen deposition with patchy areas of more confluent scarring and associated alveolar contraction. CONCLUSIONS: The development of lung fibrosis in the setting of type II cell injury in our model provides evidence for a causal link between the epithelial defects seen in idiopathic pulmonary fibrosis and the corresponding areas of scarring.
Authors: Steffen Jung; Derya Unutmaz; Phillip Wong; Gen-Ichiro Sano; Kenia De los Santos; Tim Sparwasser; Shengji Wu; Sri Vuthoori; Kyung Ko; Fidel Zavala; Eric G Pamer; Dan R Littman; Richard A Lang Journal: Immunity Date: 2002-08 Impact factor: 31.745
Authors: Y Morishima; A Nomura; Y Uchida; Y Noguchi; T Sakamoto; Y Ishii; Y Goto; K Masuyama; M J Zhang; K Hirano; M Mochizuki; M Ohtsuka; K Sekizawa Journal: Am J Respir Cell Mol Biol Date: 2001-01 Impact factor: 6.914
Authors: M Saito; T Iwawaki; C Taya; H Yonekawa; M Noda; Y Inui; E Mekada; Y Kimata; A Tsuru; K Kohno Journal: Nat Biotechnol Date: 2001-08 Impact factor: 54.908
Authors: Alan Q Thomas; Kirk Lane; John Phillips; Melissa Prince; Cheryl Markin; Marcy Speer; David A Schwartz; Radhika Gaddipati; Annis Marney; Joyce Johnson; Richard Roberts; Jonathan Haines; Mildred Stahlman; James E Loyd Journal: Am J Respir Crit Care Med Date: 2002-05-01 Impact factor: 21.405
Authors: Thomas H Sisson; Kerstin E Hanson; Natalya Subbotina; Anjali Patwardhan; Noboru Hattori; Richard H Simon Journal: Am J Physiol Lung Cell Mol Physiol Date: 2002-11 Impact factor: 5.464
Authors: Kevin R Flaherty; Jeanette A Mumford; Susan Murray; Ella A Kazerooni; Barry H Gross; Thomas V Colby; William D Travis; Andrew Flint; Galen B Toews; Joseph P Lynch; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2003-05-28 Impact factor: 21.405
Authors: K R Flaherty; E L Thwaite; E A Kazerooni; B H Gross; G B Toews; T V Colby; W D Travis; J A Mumford; S Murray; A Flint; J P Lynch; F J Martinez Journal: Thorax Date: 2003-02 Impact factor: 9.139
Authors: Kamran Atabai; Masanobu Ishigaki; Thomas Geiser; Iris Ueki; Michael A Matthay; Lorraine B Ware Journal: Am J Physiol Lung Cell Mol Physiol Date: 2002-07 Impact factor: 5.464
Authors: Mark A Barnes; Megan R McMullen; Sanjoy Roychowdhury; Nabil Z Madhun; Kathryn Niese; Mitchell A Olman; Abram B Stavitsky; Richard Bucala; Laura E Nagy Journal: J Leukoc Biol Date: 2014-11-14 Impact factor: 4.962
Authors: Jonathan M Rubin; Jeffrey C Horowitz; Thomas H Sisson; Kang Kim; Luis A Ortiz; James D Hamilton Journal: Ultrasound Med Biol Date: 2016-08-10 Impact factor: 2.998